Semaglutide before and after 1 month: what the trial data actually shows

What the trial data says about weight loss at one month

The STEP 1 trial is the most cited evidence base for semaglutide 2.4 mg (Wegovy) in weight management. Its headline figure (roughly 15% average body-weight reduction) comes from 68 weeks of treatment. The first month of that trial represents the 0.25 mg starting phase, a dose chosen specifically for its tolerability profile rather than its therapeutic effect. Published data from the trial does not report a discrete one-month weight-loss figure in isolation, because that is not how the evidence was designed to show efficacy.

What the data does show is that weight loss with semaglutide is gradual and cumulative. Participants were titrated through escalating doses over several months before reaching the 2.4 mg maintenance dose. The bulk of the recorded weight loss occurred during and after that maintenance phase. Expecting a large number at week four sets a benchmark the trial itself never used.

That said, the trial did capture consistent early signals: reduced appetite, lower food intake and some initial weight change were present in the early weeks for many participants. These subjective changes (eating smaller portions, feeling satisfied sooner) are often the first thing people notice, and they matter even when the scales have not moved much.

For a fuller picture of how results accumulate beyond the first four weeks, the two-month semaglutide results page covers what the trial data shows as doses begin to increase.

Why the first four weeks look different from what people expect

There is a widespread assumption that GLP-1 medicines produce fast, dramatic results from day one. It is understandable, the overall weight-loss figures are genuinely significant, and they circulate widely. But the timeline matters. A common misconception is that a modest first month means the medicine is not working. It does not. It means the medicine is doing exactly what it is designed to do in week one through four: establishing tolerability, allowing your gut to adjust, and beginning to shift appetite signalling, not delivering the full effect that builds over many subsequent months.

The NHS patient information for semaglutide confirms that treatment begins at a low dose with regular increases, and that the prescriber guides timing based on how each person responds. Rushing that schedule is clinically inadvisable.

What people commonly report during month one: reduced hunger, sometimes nausea or mild digestive discomfort (particularly in the first week after a dose), a smaller appetite at meals, and some early weight change, typically a few kilograms, though this varies considerably. Results at a broader look at semaglutide before-and-after outcomes show how that early picture develops over longer timeframes.

Men often ask whether their experience differs from women's at this stage. The semaglutide results in men page covers what the evidence says about sex-related variation.

Side effects in the first month and what to watch for

The side-effect profile of semaglutide is well characterised. Gastrointestinal effects (nausea, loose stools, indigestion, reduced appetite to the point of early fullness) are the most frequently reported, and they tend to be most noticeable in the first weeks of treatment or after a dose increase. For most people they are mild to moderate and ease as the body adjusts.

A smaller number of people experience more significant GI symptoms. If you cannot keep fluids down, become dehydrated, or develop severe and persistent stomach pain that reaches through to your back, that requires prompt medical attention. The MHRA has issued guidance on pancreatitis as an infrequent but serious consideration with GLP-1 medicines; the Yellow Card scheme is the way to report any suspected side effects from your treatment.

Injection-site reactions (redness, mild bruising or itching at the site) are also common in early treatment and generally settle with good technique and rotation between sites.

Semaglutide is not recommended during pregnancy, breastfeeding or for those actively trying to conceive. It is not licensed for under-18s. Anyone with a history of certain thyroid conditions or pancreatitis should raise this with a prescriber before starting.

Questions about how long the adjustment period lasts are common; how long Wegovy takes to work covers the full timeline in detail.

What one month on semaglutide can realistically look like

Setting a realistic frame for month one matters. The clinical evidence points to appetite change and early weight reduction rather than large numbers. A person who starts at 100 kg and loses 2–3 kg in the first month is tracking well, that is broadly consistent with what the dose schedule produces at this stage. Someone who loses more may be responding quickly to even the starter dose; someone who loses less may still be in a normal adjustment phase.

The key metric for month one is not the number on the scales. It is whether the medicine is tolerable, whether appetite is beginning to shift, and whether the prescriber is satisfied that titration should continue. Three months is a more meaningful checkpoint for early efficacy, see what semaglutide results look like at three months for context on that window.

Semaglutide 2.4 mg (Wegovy) is a prescription-only medicine, and the right starting point is a clinical assessment. If you are considering treatment, our Wegovy information page covers the licence, the evidence and how the process works, or you can read about weight-loss treatment options more broadly before deciding.

Our prescribers review every consultation personally, a real clinician reads your answers, the same day. Start your free consultation if you would like to talk through whether semaglutide is suitable for you.